DK2533047T3 - CCR4 as a therapeutic target for cancer - Google Patents

CCR4 as a therapeutic target for cancer Download PDF

Info

Publication number
DK2533047T3
DK2533047T3 DK12182790.1T DK12182790T DK2533047T3 DK 2533047 T3 DK2533047 T3 DK 2533047T3 DK 12182790 T DK12182790 T DK 12182790T DK 2533047 T3 DK2533047 T3 DK 2533047T3
Authority
DK
Denmark
Prior art keywords
ccr4
cancer
cells
agent
tumor
Prior art date
Application number
DK12182790.1T
Other languages
Danish (da)
English (en)
Inventor
Violet Slettenaar
Julia Wilson
Yaohe Wang
Tiziana Schioppa
Frances Balkwill
Original Assignee
Cancer Res Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38670078&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2533047(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cancer Res Tech Ltd filed Critical Cancer Res Tech Ltd
Application granted granted Critical
Publication of DK2533047T3 publication Critical patent/DK2533047T3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G01N33/575—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK12182790.1T 2007-09-18 2008-09-18 CCR4 as a therapeutic target for cancer DK2533047T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0718167A GB0718167D0 (en) 2007-09-18 2007-09-18 Cancer marker and therapeutic target
EP08806315.1A EP2176664B1 (en) 2007-09-18 2008-09-18 Ccr4 as cancer marker

Publications (1)

Publication Number Publication Date
DK2533047T3 true DK2533047T3 (en) 2016-08-22

Family

ID=38670078

Family Applications (3)

Application Number Title Priority Date Filing Date
DK12182790.1T DK2533047T3 (en) 2007-09-18 2008-09-18 CCR4 as a therapeutic target for cancer
DK12183760.3T DK2535716T3 (en) 2007-09-18 2008-09-18 Cancer marker and therapeutic target
DK08806315.1T DK2176664T3 (da) 2007-09-18 2008-09-18 Ccr4 som cancermarkør

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK12183760.3T DK2535716T3 (en) 2007-09-18 2008-09-18 Cancer marker and therapeutic target
DK08806315.1T DK2176664T3 (da) 2007-09-18 2008-09-18 Ccr4 som cancermarkør

Country Status (11)

Country Link
US (2) US9134293B2 (enExample)
EP (3) EP2533047B1 (enExample)
JP (2) JP5774309B2 (enExample)
AU (1) AU2008300413B2 (enExample)
CA (1) CA2699702C (enExample)
DK (3) DK2533047T3 (enExample)
ES (3) ES2588507T3 (enExample)
GB (1) GB0718167D0 (enExample)
PL (3) PL2176664T3 (enExample)
RU (2) RU2529797C2 (enExample)
WO (1) WO2009037454A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0623815Y2 (ja) 1988-10-06 1994-06-22 株式会社大金製作所 エア回転継手のシール装置
GB0718167D0 (en) 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target
US9229004B2 (en) 2008-09-26 2016-01-05 The General Hospital Corporation Methods for detecting and treating cancer
US11029313B2 (en) 2008-09-26 2021-06-08 The General Hospital Corporation Method of treating cervical neoplasia in patients infected with human papilloma virus
GB0909906D0 (en) 2009-06-09 2009-07-22 Affitech As Antibodies
WO2011157678A1 (en) * 2010-06-14 2011-12-22 Qiagen Gmbh Method for determination of target cells or tissue for extraction of biomolecules from fixed biological samples
GB201021289D0 (en) * 2010-12-15 2011-01-26 Immatics Biotechnologies Gmbh Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
US10266599B2 (en) 2010-12-07 2019-04-23 Cancer Research Technology Limited Antibodies which bind to the human CC chemokine receptor 4 and uses thereof
GB201020738D0 (en) 2010-12-07 2011-01-19 Affitech Res As Antibodies
HK1212389A1 (en) 2011-10-24 2016-06-10 Signalchem Lifesciences Corporation Carbonic anhydrase ix-related markers and use thereof
WO2013082490A1 (en) 2011-12-01 2013-06-06 Chemocentryx, Inc. Substituted anilines as ccr(4) antagonists
GB2512857A (en) * 2013-04-09 2014-10-15 Cancer Res Technology Cancer biomarker
WO2015069865A1 (en) * 2013-11-06 2015-05-14 Janssen Biotech, Inc. Anti-ccl17 antibodies
WO2015184099A1 (en) 2014-05-28 2015-12-03 4-Antibody Ag Anti-gitr antibodies and methods of use thereof
SG11201702053TA (en) * 2014-10-01 2017-04-27 Sphingotec Gmbh Hgh determination for use to guide prevention of a major adverse cardiac event or a cardiovascular disease in a subject
CN107624071A (zh) * 2015-04-17 2018-01-23 诺福泰克公司 肺癌治疗方法
EP3329244B1 (en) 2015-07-30 2022-10-05 Qiagen GmbH Method of preparing a frozen biological sample
WO2017096179A1 (en) 2015-12-02 2017-06-08 Agenus Inc. Antibodies and methods of use thereof
EP3626269A4 (en) 2017-05-19 2021-03-03 Shingo Maeda METHOD FOR INFILTRATION OF REGULATORY T-CELLS USING CCR4 INHIBITION AND METHOD FOR TREATMENT OF NEOPLASTIC DISEASES IN DOGS
EP3843734A4 (en) 2018-08-29 2022-05-25 ChemoCentryx, Inc. COMBINATION THERAPY USING C-CHEMOCINE RECEPTOR 4 (CCR4) ANTAGONISTS AND ONE OR MORE IMMUNE CHECKPOINT INHIBITORS

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5786158A (en) * 1992-04-30 1998-07-28 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US5342947A (en) * 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
WO1994021814A1 (en) * 1993-03-19 1994-09-29 The Johns Hopkins University Antibodies and assays for determining mutations in the apc gene
GB9501683D0 (en) 1995-01-27 1995-03-15 Glaxo Group Ltd Substances and their uses
US6498015B1 (en) 1995-06-07 2002-12-24 Icos Corporation Methods of identifying agents that modulate the binding between MDC and an MDC receptor
US6245332B1 (en) 1999-01-15 2001-06-12 The Board Of Trustees Of The Leland Stanford Junior University Modulation of systemic memory T cell trafficking
US6488930B1 (en) * 1999-01-15 2002-12-03 Millennium Pharmaceuticals, Inc. Anti-CCR4 antibodies and methods of use therefor
AU3607301A (en) 2000-03-03 2001-09-12 Kyowa Hakko Kogyo Kk Gene recombinant antibody and its fragment
WO2002030357A2 (en) 2000-10-11 2002-04-18 Chemocentryx, Inc. Compounds and methods for modulating ccr4 function
US20020173524A1 (en) 2000-10-11 2002-11-21 Tularik Inc. Modulation of CCR4 function
CA2423020C (en) 2000-10-18 2009-01-20 Schering Aktiengesellschaft Use of antiprogestins for the induction of apoptosis in a cell
JP2004535157A (ja) * 2001-02-28 2004-11-25 プロテイン デザイン ラブス， インコーポレイテッド ケモカイン受容体と疾患
WO2002094264A1 (en) 2001-05-23 2002-11-28 Tularik Inc. Ccr4 antagonists
JP2005509408A (ja) 2001-08-10 2005-04-14 トピジェン・ファルマスーティック・インコーポレーテッド 細胞ウイルス受容体およびその使用方法
BRPI0212266B8 (pt) 2001-08-31 2021-05-25 Kyowa Hakko Kirin Co Ltd anticorpos humanizados anti-ccr4, método de produção dos mesmos, medicamento, e agentes terapêuticos e de diagnóstico
US20060004010A1 (en) 2002-07-10 2006-01-05 Hiromu Habashita Ccr4 antagonist and medical use thereof
AU2003291549A1 (en) 2002-11-15 2004-06-15 Morehouse School Of Medicine Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms
EP1592708A2 (en) * 2003-02-14 2005-11-09 Sagres Discovery, Inc. Therapeutic gpcr targets in cancer
US7807389B2 (en) 2003-03-14 2010-10-05 University Of Rochester Methods and compositions related to joint inflammation diseases
SE0301650D0 (sv) 2003-06-04 2003-06-04 Astrazeneca Ab Novel compounds
SE0301653D0 (sv) 2003-06-05 2003-06-05 Astrazeneca Ab Novel compounds
US7732442B2 (en) 2003-09-05 2010-06-08 Ono Pharmaceutical Co., Ltd. Chemokine receptor antagonist and medical use thereof
EP1688436A4 (en) * 2003-10-08 2009-12-02 Kyowa Hakko Kirin Co Ltd ANTIBODY COMPOSITION THAT IS ABLE TO SPECIFY CCR4 SPECIFICALLY
ATE486611T1 (de) 2003-12-04 2010-11-15 Kyowa Hakko Kirin Co Ltd Einen genetisch modifizierten antikörper gegen chemokin-rezeptor-ccr4 enthaltendes medikament
WO2005082865A1 (ja) 2004-02-27 2005-09-09 Astellas Pharma Inc. 縮合二環性ピリミジン誘導体
JP2007217282A (ja) 2004-03-04 2007-08-30 Astellas Pharma Inc 置換ピリミジン誘導体
WO2005106471A2 (en) 2004-04-30 2005-11-10 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with c-c chemokine receptor 4 (ccr4)
JP2007269629A (ja) 2004-06-21 2007-10-18 Astellas Pharma Inc キナゾリン誘導体
RU2296328C1 (ru) * 2005-09-21 2007-03-27 Общество с ограниченной ответственностью "ГЕН" Способ определения предрасположенности к онкологическим заболеваниям и диагностический набор для его осуществления
EP1777523A1 (en) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
EP2365080B1 (en) 2006-02-14 2016-04-13 NOXXON Pharma AG MCP-1 binding nucleic acids
GB0718167D0 (en) 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target

Also Published As

Publication number Publication date
AU2008300413A1 (en) 2009-03-26
ES2443541T3 (es) 2014-02-19
EP2535716B1 (en) 2016-11-02
JP2010539508A (ja) 2010-12-16
GB0718167D0 (en) 2007-10-31
RU2529797C2 (ru) 2014-09-27
EP2535716A3 (en) 2013-03-13
JP6234967B2 (ja) 2017-11-22
US20100278844A1 (en) 2010-11-04
RU2010123921A (ru) 2011-12-20
PL2533047T3 (pl) 2016-11-30
EP2533047A1 (en) 2012-12-12
CA2699702C (en) 2018-03-06
US9134293B2 (en) 2015-09-15
EP2176664A2 (en) 2010-04-21
WO2009037454A3 (en) 2009-05-07
PL2535716T3 (pl) 2017-06-30
JP2015212703A (ja) 2015-11-26
JP5774309B2 (ja) 2015-09-09
EP2535716A2 (en) 2012-12-19
RU2014128513A (ru) 2016-02-10
PL2176664T3 (pl) 2014-04-30
US10261099B2 (en) 2019-04-16
EP2176664B1 (en) 2013-11-06
DK2176664T3 (da) 2014-01-20
CA2699702A1 (en) 2009-03-26
AU2008300413B2 (en) 2014-09-11
ES2588507T3 (es) 2016-11-03
EP2533047B1 (en) 2016-05-11
DK2535716T3 (en) 2017-02-13
ES2612690T3 (es) 2017-05-18
WO2009037454A2 (en) 2009-03-26
US20160223572A1 (en) 2016-08-04

Similar Documents

Publication Publication Date Title
DK2533047T3 (en) CCR4 as a therapeutic target for cancer
Wang et al. High expression of CXCR4, CXCR7 and SDF-1 predicts poor survival in renal cell carcinoma
CN102421919B (zh) 采用Axl作为上皮‑间质转化的生物标志物的方法
HuangFu et al. Inflammatory signaling compromises cell responses to interferon alpha
JP2016001187A (ja) 抗体ベースのアレイを使用する胃癌療法のための薬物選択
CN102667484A (zh) 识别黑素瘤肿瘤细胞的生物标记
Funk et al. High S100A8 and S100A12 protein expression is a favorable prognostic factor for survival of oropharyngeal squamous cell carcinoma
MX2010009140A (es) Seleccion de farmacos para terapia de cancer de mama utilizando matrices basadas en anticuerpos.
Kim et al. B7-H3 and B7-H4 expression in breast cancer and their association with clinicopathological variables and T cell infiltration
Aghajani et al. Epithelial-to-mesenchymal transition and its association with PD-L1 and CD8 in thyroid cancer
Hermida-Prado et al. Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
Dubuisson et al. Immunodynamics of explanted human tumors for immuno‐oncology
Mink et al. Evaluation of Nectin-4 and Trop-2: implications for patient outcomes and therapy in penile cancer
Van Berckelaer et al. XIAP overexpressing inflammatory breast cancer patients have high infiltration of immunosuppressive subsets and increased TNFR1 signaling targetable with Birinapant
AU2013203369B2 (en) Cancer marker and therapeutic target
KR20230072259A (ko) Prrx1 억제제를 포함하는 암 예방 또는 치료용 약학 조성물
KR102528973B1 (ko) 면역항암요법에 대한 바이오마커 및 이의 용도
Yang Upregulation of CD112R (PVRIG) and PD-1 on cytotoxic T-cells located in T-cell niche of colorectal cancer
Gouravski Assessing ER Positive Breast Cancer Heterogeneity and Identification of Tumour Microenvironment Molecular Markers in Response to Treatment Via Multi-omic Approach
Wong Role of Overexpression of Lymphotoxin in Ovarian Cancer Growth
KR20220156855A (ko) 체크포인트 저해제에 대한 응답을 예측하기 위한 바이오마커
DeRycke S100A1 and nectin 4 biomarkers in ovarian cancer
Berghuis et al. Sa ola